• Mattia Rosso, Brian C Healy, Shrishti Saxena, Anu Paul, Kjetil Bjornevik, Jens Kuhle, Pascal Benkert, David Leppert, Charles Guttmann, Rohit Bakshi, Howard L Weiner, and Tanuja Chitnis.
• Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
• J Neuroimaging. 2021 Mar 1; 31 (2): 388-393.

Background And PurposeSerum neurofilament light (sNfL) has been studied as a biomarker of disease activity in multiple sclerosis (MS). Several factors, including age, can influence its dynamics, and several studies have shown that sNfL increases with age in controls. Our objective was to explore the relationship of sNfL and age at different MS disease stages, including remission and after a gadolinium-enhancing (Gad+) lesion.MethodsWe included 94 patients with MS with annual sNfL measurements performed with a single-molecule array assay. We used multivariable linear mixed-effects models with random intercept to test the association between age and sNfL during remission and after a Gad+ lesion (ie, within 90 days after the Gad+ lesion). The model was adjusted for medication use and sex.ResultsWe report a positive association between sNfL level and age during remission (adjusted estimate = 1.18% yearly increase, 95% CI = .34-2.03%, P = .008). In contrast, a negative interaction between age and Gad+ lesion status was observed (adjusted estimate = -1.73%, 95% CI = -2.85 to -.58%, P = .004).ConclusionWe propose that younger patients experience a greater elevation in sNfL than older patients in response to Gad+ lesions. Our study provides potential insights into the effects of aging on neuroinflammation in MS.© 2021 American Society of Neuroimaging.

19 keywords...

hide…